PAIS 2 (Paracetamol [Acetaminophen] in Stroke 2): Results of a Randomized, Double-Blind Placebo-Controlled Clinical Trial

• Published in: Stroke (1970) Vol. 48; no. 4; pp. 977 - 982
• Main Authors: de Ridder, Inger R, den Hertog, Heleen M, van Gemert, H. Maarten A, Schreuder, A.H.C.M.L (Tobien), Ruitenberg, Annemieke, Maasland, E (Lisette), Saxena, Ritu, van Tuijl, Jordie H, Jansen, Ben P.W, Van den Berg-Vos, Renske M, Vermeij, Frederique, Koudstaal, Peter J, Kappelle, L Jaap, Algra, Ale, van der Worp, H Bart, Dippel, Diederik W.J, Lingsma, H.F, El Ghannouti, N, Vermey, F, Vermeulen, M, Tijssen, J.G.P, van Dijk, E.J
• Format: Journal Article
• Language: English
• Published: United States American Heart Association, Inc 01.04.2017
• Subjects: Acetaminophen - administration & dosage; Acetaminophen - pharmacology; Aged; Aged, 80 and over; Antipyretics - administration & dosage; Antipyretics - pharmacology; Brain Ischemia - complications; Cerebral Hemorrhage - complications; Double-Blind Method; Female; Fever - drug therapy; Fever - etiology; Humans; Male; Middle Aged; Outcome Assessment (Health Care); Stroke - complications; Stroke - drug therapy; Stroke - etiology; acetaminophen; body temperature; stroke; treatment outcome; therapy
• ISSN: 0039-2499; 1524-4628
• DOI: 10.1161/STROKEAHA.116.015957

BACKGROUND AND PURPOSE—Subfebrile body temperature and fever in the first days after stroke are strongly associated with unfavorable outcome. A subgroup analysis of a previous trial suggested that early treatment with paracetamol may improve functional outcome in patients with acute stroke and a body temperature of ≥36.5°C. In the present trial, we aimed to confirm this finding. METHODS—PAIS 2 (Paracetamol [Acetaminophen] in Stroke 2) was a multicenter, randomized, double-blind, placebo-controlled clinical trial. We aimed to include 1500 patients with acute ischemic stroke or intracerebral hemorrhage within 12 hours of symptom onset. Patients were treated with paracetamol in a daily dose of 6 g or matching placebo for 3 consecutive days. The primary outcome was functional outcome at 3 months, assessed with the modified Rankin Scale and analyzed with multivariable ordinal logistic regression. Because of slow recruitment and lack of funding, the study was stopped prematurely. RESULTS—Between December 2011 and October 2015, we included 256 patients, of whom 136 (53%) were allocated to paracetamol. In this small sample, paracetamol had no effect on functional outcome (adjusted common odds ratio, 1.15; 95% confidence interval, 0.74–1.79). There was no difference in the number of serious adverse events (paracetamol n=35 [26%] versus placebo n=28 [24%]). CONCLUSIONS—Treatment with high-dose paracetamol seemed to be safe. The effect of high-dose paracetamol on functional outcome remains uncertain. Therefore, a large trial of early treatment with high-dose paracetamol is still needed. CLINICAL TRIAL REGISTRATION—URLhttp://www.trialregister.nl. Unique identifierNTR2365.